Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
The gunman who shot and killed an NYPD officer and three other people in midtown Manhattan on Monday carried a handwritten note claiming he had CTE — a degenerative brain disease that is the result of ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Career and technical education programs are on the rise and appear poised for greater expansion. Well over half (61%) of educators report their districts have increased their CTE offerings over the ...
It isn’t yet possible to diagnose chronic traumatic encephalopathy—more widely known as CTE—in the living. Yet for many people, especially athletes, the fear is real. In fact, 1 in 3 former NFL ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback